Multi-year, pan-portfolio deal extends Adaptive’s proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology

See original here:
Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of...

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *